Synthetic Biology Patents: Top Companies & Filing Trends 2026
- Concentrated but not locked up. the ranked leader holds 221 records, yet the top 5 combined account for only 26.7% of all 2,511 records in scope — most of the field sits with a long tail of single- and few-filing entrants.
- Filing kept climbing through 2024. annual filings rose from 174 in 2021 to 224 in 2024, a 29% increase, with a peak of 238 in 2023 — 2025 and 2026 figures are still filling in due to publication lag.
- Genetic engineering claims dominate the class mix. C12N (microorganisms & genetic engineering) appears on 47.5% of all records, more than three times the share of B01L (lab apparatus) at 4.4%, signalling where claim space is most crowded and where it is comparatively open.
Filing growth compares 2021 (174 records) with 2024 (224) — a three-year span. 2024 is the most recent year we treat as complete: publication lags filing by roughly 18 months, so 2025 onwards are still filling in and any growth rate that ends there would understate the field. Top-5 share is the combined record count of the five largest assignees divided by all 2,511 records in scope (CR5), not by the ranked leaders only.
What this landscape covers
This dataset tracks 2,511 patent records published between 2015 and mid-2026 that combine synthetic biology or biomanufacturing terms with specific process concepts — yeast chassis, precision fermentation, bioprocess scale-up, downstream bioprocessing, cell-free biomanufacturing, biofoundry automation and engineered biological systems. It spans core genetic engineering work through to the bioreactor, separation and quality-control hardware that turns an engineered organism into a manufactured product.
Filing activity has grown steadily rather than exploded, with the strongest concentration of records sitting in microorganism engineering and fermentation classes. Receiving-office data shows the United States as the dominant single jurisdiction, with WIPO PCT filings and the European Patent Office both carrying substantial volume, indicating that applicants are pursuing multi-jurisdiction protection rather than filing domestically alone.
Let an AI agent run this analysis on your own technology
Pick a task. Every answer cites the patents behind it.
Filing trends and technology composition
Two views of the same 2,511-record dataset: the pace of filing over time, and how those records distribute across International Patent Classification subclasses.
Filing trend, 2017–2026
Annual filings rose from 147 in 2017 to a peak of 238 in 2023, with 2021-to-2024 growth of 29% (174 to 224). The 2025 and 2026 counts are understated because publication typically lags filing by roughly 18 months.
Technology composition by IPC subclass
C12N (microorganisms & genetic engineering) leads at 47.5% of the 2,511 records, followed by C12P (fermentation & enzymatic synthesis) at 31.1% and C12M (bioreactors & enzyme apparatus) at 23.7%. Records can carry more than one class, so these shares sum to more than 100%.
Shares are the percentage of the 2,511 records in scope. A patent can carry several IPC classes, so the shares add up to more than 100%.
Go deeper on Synthetic Biology & Biomanufacturing Patent Landscape with Eureka
This page is one run against one query. Ask Eureka your own question about synthetic biology & biomanufacturing patent landscape and every answer comes back with the patent numbers behind it.
Try EurekaRepresentative filing and most-cited records
US6395538B1 — Real-time biomanufacturing process monitoring via IR spectroscopy
A method and system for providing real-time, in situ biomanufacturing process monitoring and control in response to infra-red spectroscopic fingerprinting of a biomolecule. Fourier Transform Infra-red spectroscopy is used to determine whether an active or aged biomolecule is present across the four stages of a biomanufacturing process: bioproduction, recovery, purification and bulk storage.Filed by Human Genome Sciences and granted in 2002, this record predates most of the dataset and anchors process-monitoring claims that later fermentation and bioprocessing filings had to navigate around.
| # | Publication no. | Patent title | Citations |
|---|---|---|---|
| 1 | US20050043894A1 | Integrated biosensor and simulation system for diagnosis and therapy | 719 |
| 2 | US20050124010A1 | Whole cell engineering by mutagenizing a substantial portion of a starting genome combining mutations and opt… | 268 |
| 3 | US20170341942A1 | Methods and systems for large scale carbon dioxide utilization from lake KIVU via a co2 industrial utilizatio… | 208 |
| 4 | WO2017189308A1 | Novel crispr enzymes and systems | 204 |
| 5 | WO1996035796A1 | Bioconversion of a fermentable carbon source to 1,3-propanediol by a single microorganism | 199 |
| 6 | US6245555B1 | Method and apparatus for aseptic growth or processing of biomass | 190 |
| 7 | US20100285082A1 | Integrated Biosensor and Simulation System for Diagnosis and Therapy | 183 |
| 8 | WO2009094485A1 | Methods and organisms for utilizing synthesis gas or other gaseous carbon sources and methanol | 182 |
| 9 | WO2017184768A1 | Novel crispr enzymes and systems | 173 |
| 10 | WO2002029032A2 | Whole cell engineering by mutagenizing a substantial portion of a starting genome, combining mutations, and o… | 162 |
Citation counts favour older records simply because they have had more time to accumulate citations within the searched corpus — treat them as a signal of influence, not of current technical importance.
Each row carries its publication number; clicking a row searches Eureka by that number.
Put your own technology through the same analysis
Eureka on the web
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →MCP server & REST API
When it has to run inside your own pipeline.
Patent search, landscape analysis and assignee resolution as MCP tools. Drop them into any agent framework, or call REST directly.
Browse MCP servers →What the numbers mean for a filing decision
Read together, the concentration, growth and class data point to a field that is still open at the edges even where the centre is crowded.
The centre is crowded, the edges are not
A single leader holds 221 records against a fifth-place figure of 66 and a tenth-place figure of 39 — a steep drop-off that signals a long tail of entrants with only a handful of filings each. Freedom-to-operate work should focus less on out-filing the leader and more on mapping which specific claim elements the leading cluster actually owns.
Growth has been steady, not explosive
The three-year rise from 174 to 224 annual filings, with a peak of 238 in 2023, shows sustained rather than spiking investment. Because publication lags filing by about 18 months, the lower counts shown for 2025 and 2026 understate real activity and should not be read as a slowdown.
Genetic engineering claims dominate; lab apparatus does not
C12N appears on nearly half of all records, more than ten times the share carried by B01L lab apparatus claims. That gap is a filing signal: apparatus and instrumentation claims around biofoundry and lab-scale automation carry far less prior art density than the underlying organism-engineering claims.
US-first filing with broad international follow-through
The United States receives the largest single share of filings, but PCT and EPO volumes both exceed the next-largest national offices, indicating that most serious applicants are pursuing multi-jurisdiction coverage rather than domestic-only protection.
Eureka can read the same corpus for gaps instead of for coverage: under-claimed branches adjacent to synthetic biology & biomanufacturing patent landscape, with the prior art for and against each one.
Who is filing, and where they are pulling back
The ranked leaders combine large industrial biotech filers, academic institutions and specialist bioprocessing suppliers, but recent-year momentum data suggests several long-standing leaders have slowed sharply.
A single large filer sets the pace
The leading assignee's record count is more than three times that of the fifth-ranked filer, reflecting a sustained, multi-year filing programme rather than a short burst tied to a single product line.
Some long-standing filers have gone quiet
Recent-year momentum data shows multiple established assignees, including academic and research institutions, dropping to zero filings in the latest year after sustained prior activity. That does not necessarily mean exit from the field — it may reflect filing-to-publication lag or a shift to a different assignee entity.
Academic co-filing is concentrated in one partnership
The strongest co-assignee pairing in the dataset, an academic-institute pairing, accounts for far more joint records than any other pair, while the next strongest pairs are built around individual named inventors rather than institutions.
| Assignee | Recent year | YoY |
|---|---|---|
| Genzyme Corp | 1 | -80% |
| Genomatica Inc | 0 | — |
| Massachusetts Institute of Technology | 0 | -100% |
| The Broad Institute Inc | 0 | -100% |
| Kiverdi Inc | 0 | -100% |
| North Carolina State University | 0 | -100% |
| BURGARD ANTHONY P | 0 | — |
| BioStructures Lab Inc | 0 | — |
Where to take this analysis
The dataset points to specific next steps depending on whether the goal is freedom-to-operate, whitespace filing, or tracking a competitor.
Map claims against the leading cluster
Before filing in C12N or C12P, check which specific claim elements the top-ranked assignees hold rather than assuming the whole class is blocked — concentration is high but not absolute.
Explore assignee claims in EurekaWatch momentum shifts, not just totals
Several long-standing filers show sharp year-over-year drops; confirm whether that reflects publication lag or an actual change in strategy before treating them as inactive.
Track filer momentum in EurekaTest whitespace in apparatus classes
Lab apparatus and bioprocess monitoring carry markedly lower claim density than core genetic-engineering classes, which may leave room for narrower, defensible filings.
Run a whitespace search in EurekaCommon questions about this landscape
The dataset ranks 100 assignees by patent family count, with the leading filer holding 221 records against 66 at fifth place and 39 at tenth place. That drop-off shows a concentrated top tier followed by a long tail of companies and institutions with far fewer filings each. The leading names combine large industrial biotech firms, major research universities, and specialist bioprocessing equipment suppliers, so no single type of organisation dominates the field outright.
Filing activity grew from 174 records in 2021 to 224 in 2024, a 29% increase, with a peak of 238 filings in 2023. It is not accurate to describe the field as slowing based on 2025 or 2026 counts, because patent publication typically lags filing by around 18 months, so the most recent years in any trend chart are always understated. The complete picture through 2024 shows sustained growth rather than a plateau.
C12N, covering microorganisms and genetic engineering, appears on 47.5% of the 2,511 records in this dataset, making it the single most heavily claimed subclass. C12P (fermentation and enzymatic synthesis) and C12M (bioreactors and enzyme apparatus) follow at 31.1% and 23.7% respectively. Because a single patent record can carry multiple IPC classes, these percentages add up to more than 100% and should be read as independent measures of claim density rather than shares of a whole.
Lab-scale apparatus (B01L) carries claims on only 4.4% of records, a far lower density than the 47.5% carried by core genetic-engineering claims, suggesting more room to file defensible apparatus and automation patents than organism-engineering ones. Cell-free biomanufacturing and biofoundry automation are specific branches named in the search scope that show comparatively thin representation relative to fermentation and genetic engineering. Any whitespace claim should still be checked against the most-cited records in the relevant class before filing, since citation volume flags where prior art is concentrated even outside the top classes.
The United States receives the largest number of filings in this dataset at 792, ahead of WIPO PCT applications at 491 and European Patent Office filings at 382. Australia, Canada and India each show meaningfully lower but still substantial volumes. The pattern of strong PCT and EPO activity alongside the US lead indicates that serious applicants in this field are pursuing coverage across multiple jurisdictions rather than filing only at home.
Research Synthetic Biology & Biomanufacturing Patent Landscape in depth with Eureka
Go past this page: query the whole synthetic biology & biomanufacturing patent landscape corpus yourself, in your own scope.
Every answer comes back with patent numbers you can open.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.
Machine translation. Assignee and organisation names originally recorded in Chinese, Japanese or Korean have been rendered into English by an AI translation step so that the tables stay readable. These renderings are best-effort and may not match a company’s registered English name; the original name is what the underlying patent record carries, and it is what any Eureka query launched from this page uses.